← 返回

肝细胞癌中的免疫抑制性肿瘤微环境——现状与展望

英文原题:The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.

查看英文原题

The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.

PubMed 2022/09/27(内容时间) Mol Immunol Q2 · IF 3.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝细胞癌(HCC)是威胁人类健康的最严重恶性肿瘤之一,其发病率近年来仍呈上升趋势。尽管目前出现了新的治疗策略,但肝癌的整体预后仍令人担忧。目前,免疫治疗已成为新的研究热点。免疫检查点和靶向免疫细胞治疗的出现可显著改善HCC的预后。这种免疫治疗的效果在很大程度上取决于肿瘤免疫微环境(TME),这是一个复杂的系统,其中癌细胞和其他非癌细胞表现出各种相互作用。了解这些细胞的免疫抑制情况以及癌细胞的恶性行为,可以帮助我们设计针对肿瘤的新治疗方法。因此,有必要阐明HCC的TME,以进一步改善临床治疗。本综述讨论了最新研究进展中几种免疫抑制细胞和外泌体在HCC中的功能,包括癌症相关成纤维细胞(CAFs)、肿瘤相关巨噬细胞(TAMs)、髓源性抑制细胞(MDSCs)和肿瘤相关中性粒细胞(TANs)积极相互作用以促进肿瘤进展。它进一步描述了针对它们的治疗方法以及未来需要探索的潜力。

展开英文摘要原文

Hepatocellular carcinoma (HCC) is one of the most severe malignant tumors that threaten human health, and its incidence is still on the rise recently. In spite of the current emerging treatment strategies, the overall prognosis of liver cancer remains worrying. Currently, immunotherapy has become a new research-active spot. The emergence of immune checkpoints and targeted immune cell therapy can significantly improve the prognosis of HCC.

To a large extent, the effect of this immunotherapy depends on the tumor immune microenvironment (TME), an intricate system in which cancer cells and other non-cancer cells display various interactions. Understanding the immunosuppressive situation of these cells, along with the malignant behavior of cancer cells, can assist us to design new therapeutic approaches against tumors.

Therefore, it is necessary to clarify the TME of HCC for further improvement of clinical treatment. This review discussed the functions of several immunosuppressive cells and exosomes in the latest research progress of HCC, including cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) and tumor-associated neutrophils (TANs) interacted actively to facilitate tumor progression.

It further describes the treatment methods targeting them and the potential that needs to be explored in the future.

论文信息

作者
Zhou Z、Hu Y、Wu Y、Qi Q、Wang J、Chen L、Wang F
第一作者单位
Nantong University Medical school, Affiliated Hospital of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, China.China
通讯作者单位
Nantong University Medical school, Affiliated Hospital of Nantong University, Xisi Road, No.20, Nantong, Jiangsu, China. Electronic address: richardwangf@163.com.China
文献类型
综述 · 非美国政府资助研究
期刊
Molecular immunology2022 Nov
原文标识
PubMed 36179604 · DOI 10.1016/j.molimm.2022.09.010